
2024 FDA diversity guidance: What it means and how it could impact future clinical trial outcomes
Published on July 30, 2024
The US Food and Drug Administration (FDA) released a diversity-focused draft guidance entitled “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies” on June 26, 2024. I sat down with Lya Rebelo, commercial enablement manager at Citeline, to discuss the future impact of this long-awaited guidance, how it differs from […]
